Department XIII, Discipline of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Int J Environ Res Public Health. 2023 Jan 25;20(3):2150. doi: 10.3390/ijerph20032150.
The Omicron (B.1.1.529) variant of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) had an increased rate of spreading among the general population. Although this virus mutation resulted in milder symptoms, those on the vulnerable side of the population are still in danger of developing severe symptoms. Thus, this systematic review focused on identifying the clinical outcomes of older age patients (>65) that are hospitalized with the SARS-CoV-2 Omicron variant. The research was conducted using four electronic databases (PubMed, Scopus, Web of Science, and ProQuest Central), with a search query in December 2022 that comprised the duration of the COVID-19 pandemic. The inclusion criteria comprised (1) a population of patients older than 65 years, (2) a history of hospitalization for SARS-CoV-2 infection, and (3) infection with Omicron B.1.1.529 variant. The initial search generated 295 articles, out of which six were included in the systematic review, and a total of 7398 patients. The main findings were that when looking at the elderly population, the mortality and hospitalization rates remained high. This is because older people are more vulnerable and have more comorbidities that interfere with the virus's progress. However, there is inconsistency in mortality rates, since the data reported by the included studies had different selection criteria based on the severity of the COVID-19 infection. Although no statistically significant differences were found between the unvaccinated and vaccinated groups, patients who got booster doses of vaccination had a lower likelihood of developing severe symptoms, serving as a protective factor for this population.
奥密克戎(B.1.1.529)变异株是一种严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2),其在普通人群中的传播速度加快。尽管这种病毒突变导致症状较轻,但处于弱势人群的人仍然有患严重症状的危险。因此,本系统评价集中于识别因感染 SARS-CoV-2 奥密克戎变异株而住院的老年(>65 岁)患者的临床结局。该研究使用了四个电子数据库(PubMed、Scopus、Web of Science 和 ProQuest Central),在 2022 年 12 月进行了一项检索,其中包含了 COVID-19 大流行的持续时间。纳入标准包括(1)患者年龄>65 岁,(2)有 SARS-CoV-2 感染住院史,(3)感染奥密克戎 B.1.1.529 变异株。最初的搜索产生了 295 篇文章,其中 6 篇被纳入系统评价,共有 7398 名患者。主要发现是,在观察老年人群时,死亡率和住院率仍然很高。这是因为老年人更脆弱,并且有更多的合并症会干扰病毒的进展。然而,死亡率存在不一致性,因为纳入研究报告的数据基于 COVID-19 感染的严重程度有不同的选择标准。尽管未发现未接种疫苗和接种疫苗组之间有统计学意义上的差异,但接种加强针的患者发生严重症状的可能性较低,这是该人群的一个保护因素。